ViiV Healthcare
398
26
51
283
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.8%
35 terminated/withdrawn out of 398 trials
89.0%
+2.4% vs industry average
28%
111 trials in Phase 3/4
53%
151 of 283 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (398)
Long Acting Cabotegravir Plus Rilpivirine in People Living With HIV-1 Aged ≥ 60 Years for 24 Months.
Role: collaborator
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
Role: lead
A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories
Role: lead
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
Role: lead
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
Role: lead
SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension
Role: collaborator
2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial
Role: collaborator
Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women
Role: collaborator
Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection
Role: collaborator
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
Role: collaborator
A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
Role: lead
A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants
Role: lead
A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)
Role: lead
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Role: collaborator
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
Role: collaborator
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
Role: collaborator
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
Role: lead
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
Role: collaborator
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
Role: lead
First Time in Human Study of Long Acting VH4524184 Formulations
Role: lead